Health Care

Michael McDonnell’s move from Biogen to Moderna’s board brings seasoned finance leadership, boosting Moderna’s mRNA pipeline while underscoring Biogen’s talent‑driven biotech influence.

Biohaven’s $160 M ARPA‑H grant, leadership overhaul and RISE3 trial milestone signal a bold shift toward breakthrough neurology and immunology drugs.

HSPharm’s phase‑III win: Riz‑Rez boosts overall survival in advanced NSCLC, a breakthrough that could reshape China’s oncology market and lift investor confidence.

Explore Eli Lilly’s 2026 highlights: new Alzheimer’s tests, weight‑loss surge, Canadian eczema approval, and EU price‑pressure challenges.

Carasent’s Q2 2026 report shows ARR hitting SEK 401 M amid 18% sales growth, but margin shrinkage and negative EBITDA highlight a fragile balance between revenue expansion and profitability.

Discover how Beijing SL Pharmaceutical’s genetic‑engineering pipeline could surge amid China’s biotech boom and new 30‑day FDA review pathway.

Explore why Ningbo Menovo Pharmaceutical, a quiet Chinese API maker, may hold hidden value amid China’s push for drug self‑sufficiency.

BL1107 phase‑2 failure forces Bausch + Lomb to pivot away from glaucoma, refocusing on proven eye‑care products and new R&D prospects.

Nurix Therapeutics reports Q2 2026 earnings miss, but highlights Roche partnership and protein‑level modulation pipeline, signaling continued focus on innovative treatments.

ATAI Life Sciences NV’s AtaiBeckley Inc. plans a $5.17‑share sale of 100,000 shares by a director, revealing key financial strategy and compliance for investors.